Literature DB >> 21198664

Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Biliang Hu1, April Tai, Pin Wang.   

Abstract

The increasing level of understanding of the lentivirus biology has been instrumental in shaping the design strategy of creating therapeutic lentiviral delivery vectors. As a result, lentiviral vectors have become one of the most powerful gene transfer vehicles. They are widely used for therapeutic purposes as well as in studies of basic biology, due to their unique characteristics. Lentiviral vectors have been successfully employed to mediate durable and efficient antigen expression and presentation in dendritic cells both in vitro and in vivo, leading to the activation of cellular immunity and humoral responses. This capability makes the lentiviral vector an ideal choice for immunizations that target a wide range of cancers and infectious diseases. Further advances into optimizing the vector system and understanding the relationship between the immune system and diseases pathogenesis will only augment the potential benefits and utility of lentiviral vaccines for human health.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21198664      PMCID: PMC3030993          DOI: 10.1111/j.1600-065X.2010.00967.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  186 in total

Review 1.  Helping the CD8(+) T-cell response.

Authors:  Michael J Bevan
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

2.  The role of skin-derived dendritic cells in CD8+ T cell priming following immunization with lentivectors.

Authors:  Karina Furmanov; Mazal Elnekave; Dan Lehmann; Bjorn E Clausen; Darrell N Kotton; Avi-Hai Hovav
Journal:  J Immunol       Date:  2010-03-31       Impact factor: 5.422

3.  Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo.

Authors:  Viviana Buffa; Donatella R M Negri; Pasqualina Leone; Martina Borghi; Roberta Bona; Zuleika Michelini; Daniela Compagnoni; Cecilia Sgadari; Barbara Ensoli; Andrea Cara
Journal:  Viral Immunol       Date:  2006       Impact factor: 2.257

4.  Duration of humoral immunity to common viral and vaccine antigens.

Authors:  Ian J Amanna; Nichole E Carlson; Mark K Slifka
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

Review 5.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

6.  Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy.

Authors:  Peng H Tan; Sven C Beutelspacher; Shao-An Xue; Yao-He Wang; Peter Mitchell; James C McAlister; D Frank P Larkin; Myra O McClure; Hans J Stauss; Mary A Ritter; Giovanna Lombardi; Andrew J T George
Journal:  Blood       Date:  2005-01-25       Impact factor: 22.113

Review 7.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule.

Authors:  Haiguang Yang; Kye-Il Joo; Leslie Ziegler; Pin Wang
Journal:  Pharm Res       Date:  2009-03-04       Impact factor: 4.200

9.  Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration.

Authors:  Eugenio Montini; Daniela Cesana; Manfred Schmidt; Francesca Sanvito; Maurilio Ponzoni; Cynthia Bartholomae; Lucia Sergi Sergi; Fabrizio Benedicenti; Alessandro Ambrosi; Clelia Di Serio; Claudio Doglioni; Christof von Kalle; Luigi Naldini
Journal:  Nat Biotechnol       Date:  2006-05-28       Impact factor: 54.908

10.  Cellular and humoral immunity against vaccinia virus infection of mice.

Authors:  Rong Xu; Aaron J Johnson; Denny Liggitt; Michael J Bevan
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

View more
  38 in total

1.  A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.

Authors:  Liang Xiao; Jocelyn Kim; Matthew Lim; Bingbing Dai; Lili Yang; Steven G Reed; David Baltimore; Pin Wang
Journal:  Vaccine       Date:  2012-02-05       Impact factor: 3.641

2.  Targeting of human antigen-presenting cell subsets.

Authors:  Cleo Goyvaerts; Jozef Dingemans; Kurt De Groeve; Carlo Heirman; Ellen Van Gulck; Guido Vanham; Patrick De Baetselier; Kris Thielemans; Geert Raes; Karine Breckpot
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

Review 3.  Dendritic cells of the oral mucosa.

Authors:  A-H Hovav
Journal:  Mucosal Immunol       Date:  2013-06-12       Impact factor: 7.313

4.  A tetracycline-regulated cell line produces high-titer lentiviral vectors that specifically target dendritic cells.

Authors:  Paul D Bryson; Chupei Zhang; Chi-Lin Lee; Pin Wang
Journal:  J Vis Exp       Date:  2013-06-19       Impact factor: 1.355

5.  Leucine-rich repeat-containing G protein-coupled receptor 4 facilitates vesicular stomatitis virus infection by binding vesicular stomatitis virus glycoprotein.

Authors:  Na Zhang; Hongjun Huang; Binghe Tan; Yinglei Wei; Qingqing Xiong; Yan Yan; Lili Hou; Nannan Wu; Stefan Siwko; Andrea Cimarelli; Jianrong Xu; Honghui Han; Min Qian; Mingyao Liu; Bing Du
Journal:  J Biol Chem       Date:  2017-08-23       Impact factor: 5.157

6.  Comparison of transduction efficiency among various lentiviruses containing GFP reporter in bone marrow hematopoietic stem cell transplantation.

Authors:  Nan Wang; Narendiran Rajasekaran; Tieying Hou; Leszek Lisowski; Elizabeth D Mellins
Journal:  Exp Hematol       Date:  2013-08-14       Impact factor: 3.084

7.  In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.

Authors:  Zhi Cheng; Runhong Wei; Qiuling Ma; Lin Shi; Feng He; Zixiao Shi; Tao Jin; Ronglin Xie; Baofeng Wei; Jing Chen; Hongliang Fang; Xiaolu Han; Jennifer A Rohrs; Paul Bryson; Yarong Liu; Qi-Jing Li; Bo Zhu; Pin Wang
Journal:  Mol Ther       Date:  2018-02-02       Impact factor: 11.454

8.  A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections.

Authors:  Flavia Chiuppesi; Laura Vannucci; Anna De Luca; Michele Lai; Barbara Matteoli; Giulia Freer; Roberto Manservigi; Luca Ceccherini-Nelli; Fabrizio Maggi; Mauro Bendinelli; Mauro Pistello
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

9.  LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus.

Authors:  Danit Finkelshtein; Ariel Werman; Daniela Novick; Sara Barak; Menachem Rubinstein
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

10.  Construction of lentivirus-based inhibitor of hsa-microRNA-338-3p with specific secondary structure.

Authors:  Kai Sun; Chen Guo; Hai-jun Deng; Jing-qing Dong; Shang-tong Lei; Guo-xin Li
Journal:  Acta Pharmacol Sin       Date:  2012-12-03       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.